Gelteq (NASDAQ:GELS) Issues Quarterly Earnings Results

Gelteq (NASDAQ:GELS) posted its earnings results on Tuesday. The company reported ($0.12) earnings per share for the quarter, FiscalAI reports.

Gelteq Stock Performance

Shares of NASDAQ GELS opened at $0.67 on Wednesday. The company has a 50 day simple moving average of $0.63 and a 200-day simple moving average of $0.76. Gelteq has a 1 year low of $0.39 and a 1 year high of $2.02.

Institutional Trading of Gelteq

A hedge fund recently bought a new position in Gelteq stock. Susquehanna International Group LLP acquired a new stake in Gelteq Limited (NASDAQ:GELS) during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 41,550 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned about 0.44% of Gelteq at the end of the most recent quarter.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Gelteq from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Gelteq Company Profile

Gelteq Inc is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc is based in NEW YORK.